With CRISPR in Humans On the Horizon, Will the Public Back Intellia?
By Alex Lash,
Xconomy
| 04. 29. 2016
Untitled Document
Boston — An icy March wind was blowing across the Charles River, but in the laboratory of Intellia Therapeutics, the 1970s soft-rock hit “Summer Breeze” was blasting. Chief scientific officer Tom Barnes apologized. “Usually it’s heavy metal,” he said. He pointed out a window to a local tower, visible over the Cambridge, MA rooftops, rising from a nearby neighborhood. Intellia’s new offices were somewhere near there, out of our line of sight.
The two year old company’s more fateful impending move is a push to go public. Its IPO is scheduled for next week. That means the company, working to create new medicines with arguably the biggest biomedical innovation of the 21st century—the groundbreaking form of gene editing called CRISPR-Cas9—must convince investors to bet on its future even though it lacks what so many biotech investors crave: data from human clinical trials. What will CRISPR-Cas9 do when it gets into human cells and changes their DNA?
Intellia indicated in regulatory filings Wednesday it wants to raise $85 million in an IPO, plus a few million more if all...
Related Articles
By Alondra Nelson, Science | 09.11.2025
In the United States, the summer of 2025 will be remembered as artificial intelligence’s (AI’s) cruel summer—a season when the unheeded risks and dangers of AI became undeniably clear. Recent months have made visible the stakes of the unchecked use...
By Emma McDonald Kennedy
| 09.25.2025
In the leadup to the 2024 election, Donald Trump repeatedly promised to make IVF more accessible. He made the commitment central to his campaign, even referring to himself as the “father of IVF.” In his first month in office, Trump issued an executive order promising to expand IVF access. The order set a 90-day deadline for policy recommendations for “lowering costs and reducing barriers to IVF,” although it didn’t make any substantive reproductive healthcare policy changes.
The response to the...
By Johana Bhuiyan, The Guardian | 09.23.2025
In March 2021, a 25-year-old US citizen was traveling through Chicago’s Midway airport when they were stopped by US border patrol agents. Though charged with no crime, the 25-year-old was subjected to a cheek swab to collect their DNA, which...
By Julie Métraux, Mother Jones | 09.23.2025